Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · May 2006
Case ReportsDe novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma.
X-linked agammaglobulinemia (XLA), characterized by a profound deficiency of all immunoglobulins and the absence of mature B cells, is caused by mutations in the gene encoding Bruton tyrosine kinase (BTK). Most patients have recurrent sinopulmonary infection. Infections usually occur in multiple locations across time, but single infection may be limited to one anatomic location. ⋯ This case is an important example of a possible presentation of XLA with a predominant skin manifestation, and it demonstrates that maintaining a high level of clinical suspicion is essential for the diagnosis of XLA in a child with recurrent pyoderma.
-
Ann. Allergy Asthma Immunol. · May 2006
Sex differences in hospital admissions from emergency departments in asthmatic adults: a population-based study.
Women represent the majority of adult patients hospitalized for asthma. Analyzing the course of emergency department (ED) visits before hospital admission can help understanding of the mechanisms behind the excess of hospitalizations in women. ⋯ The higher admission rates in women may be related to sex differences in the subjective perception of dyspnea, management of asthma by ED physician, or inadequate ambulatory care strategies in women and thus merit further investigation.
-
Ann. Allergy Asthma Immunol. · May 2006
Randomized Controlled Trial Multicenter StudyEfficacy and safety of roflumilast in the treatment of asthma.
The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. ⋯ These results support the emerging role of roflumilast, 500 microg/d, in the treatment of asthma.
-
Ann. Allergy Asthma Immunol. · May 2006
Randomized Controlled Trial Comparative StudyComparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children.
Despite multiple doses of beta2-agonists in the treatment of acute asthma exacerbation, significant residual airways obstruction often remains. ⋯ Although this study did not demonstrate a significant advantage in clinical score and PEFR, the trend toward additional effect of ipratropium bromide was consistent with previous studies.
-
Ann. Allergy Asthma Immunol. · Apr 2006
Randomized Controlled TrialOnce-daily evening administration of mometasone furoate in asthma treatment initiation.
In a previous study, a 200-microg once-daily evening dose of mometasone furoate dry powder inhaler (DPI) was effective in patients with asthma previously taking inhaled corticosteroids. No studies have been conducted to test the effect of a once-daily evening dose in patients previously using only short-acting beta2-adrenergic agonists (SABAs) for symptom relief. ⋯ Mometasone furoate DPI (200 microg) administered once daily in the evening significantly improves pulmonary function in patients previously using SABAs alone for asthma control.